Furthermore, by extracting the clinical information of the GSE25066 dataset to examine the robustness of the cr-TILCD8T scoring model, we found that the cr-TILCD8TSig scoring model exhibited significant prognostic differences in groups with different clinical features, such as tumor grade, tumor stage, stage_T, ER status, and PR status (Figure 8). This evidence concerns the gene PGR and neoplasm.